Israel Lowy

23.4k total citations · 7 hit papers
159 papers, 11.1k citations indexed

About

Israel Lowy is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Israel Lowy has authored 159 papers receiving a total of 11.1k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Oncology, 54 papers in Immunology and 37 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Israel Lowy's work include Cancer Immunotherapy and Biomarkers (85 papers), CAR-T cell therapy research (52 papers) and Immunotherapy and Immune Responses (32 papers). Israel Lowy is often cited by papers focused on Cancer Immunotherapy and Biomarkers (85 papers), CAR-T cell therapy research (52 papers) and Immunotherapy and Immune Responses (32 papers). Israel Lowy collaborates with scholars based in United States, Australia and Spain. Israel Lowy's co-authors include Suzanne L. Topalian, Marybeth S. Hughes, Richard M. Sherry, Richard E. Royal, Udai S. Kammula, Steven A. Rosenberg, Elizabeth Stankevich, Alan J. Korman, Catherine Lévy and Joel Picus and has published in prestigious journals such as Science, New England Journal of Medicine and Cell.

In The Last Decade

Israel Lowy

154 papers receiving 10.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

2010 2.3k citations Julie R. Brahmer, Charles G. Drake et al. Journal of Clinical Oncology profile →
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

2010 954 citations Richard E. Royal, Marybeth S. Hughes et al. profile →
Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

2006 646 citations Joseph Blansfield, Khoi Q. Tran et al. Journal of Clinical Oncology profile →
Treatment with Monoclonal Antibodies against Clostridium difficile Toxins

2010 557 citations Israel Lowy et al. profile →
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis

2007 537 citations James Chih‐Hsin Yang, Marybeth S. Hughes et al. profile →
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

2008 488 citations Israel Lowy, Alan J. Korman et al. profile →
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

2007 323 citations Lawrence Fong, Israel Lowy et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Israel Lowy

Since Specialization

Citations

This map shows the geographic impact of Israel Lowy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Israel Lowy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Israel Lowy more than expected).

Fields of papers citing papers by Israel Lowy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Israel Lowy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Israel Lowy. The network helps show where Israel Lowy may publish in the future.

Co-authorship network of co-authors of Israel Lowy

This figure shows the co-authorship network connecting the top 25 collaborators of Israel Lowy. A scholar is included among the top collaborators of Israel Lowy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Israel Lowy. Israel Lowy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase 3 trial of fianlimab + cemiplimab versus pembrolizumab in patients with previously untreated, unresectable, locally advanced or metastatic melanoma 2025 ·(unknown), (unknown), Mario Sznol, (unknown), Fang Fang, (unknown), Mark Salvati, Israel Lowy, Matthew G. Fury, Karl D. Lewis	1
2	A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer. 2024 ·Journal of Clinical Oncology ·Nashat Gabrail, Miranda Gogishvili, Tamta Makharadze, (unknown), (unknown), (unknown), Emad Ibrahim, Daniel Brungs, Luke Dreisbach, (unknown), Solange Peters, Christopher Nguyen, (unknown), Siyu Li, (unknown), Israel Lowy, Matthew G. Fury, Luca Paoluzzi, Tamar Melkadze	2
3	A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer. 2024 ·Journal of Clinical Oncology ·(unknown), Sara Bouberhan, Konstantinos Papadimitriou, Rebecca C. Arend, (unknown), Roisin E. O’Cearbhaill, David M. O’Malley, Benoît You, Antonio González-Martı́n, Judith Michels, Linda Mileshkin, Yeh Chen Lee, (unknown), Suk‐Young Yoo, (unknown), (unknown), David A. Knorr, Israel Lowy, Thomas S. Uldrick, Elizabeth Miller	7
4	A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer: Trial in progress update 2024 ·Gynecologic Oncology ·Joyce F. Liu, David M. O’Malley, (unknown), Roisin E. O’Cearbhaill, Sara Bouberhan, Kathleen N. Moore, June Y. Hou, Erika Hamilton, Suk‐Young Yoo, Bin Wang, (unknown), (unknown), David A. Knorr, Israel Lowy, Thomas S. Uldrick, Elizabeth Miller	1
5	PP.42 Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced NSCLC 2023 ·Journal of Thoracic Oncology ·Byoung Chul Cho, Grace K. Dy, Tae Min Kim, Debashis Sarker, Omid Hamid, Stephen K. Williamson, Sang‐We Kim, Hatim Husain, Shuquan Chen, (unknown), Vladimir Janković, Anne Paccaly, (unknown), Israel Lowy, Laura K. Brennan, Giuseppe Gullo	1
6	TP020/#1513 First-in-human phase 1/2 study of ubamatamab, a MUC16XCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer 2023 ·Lirias (KU Leuven) ·Kathleen N. Moore, Sara Bouberhan, Erika Hamilton, Joyce Liu, Roisin E. O’Cearbhaill, David M. O’Malley, Konstantinos Papadimitriou, (unknown), Els Van Nieuwenhuysen, Suk‐Young Yoo, Bin Wang, (unknown), Priscila Gonçalves, (unknown), Min Zhu, Israel Lowy, Thomas S. Uldrick, Elizabeth Miller	3
7	A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update. 2023 ·Journal of Clinical Oncology ·Neil H. Segal, (unknown), Eugenia Girda, Lawrence Fong, Anthony J. Olszanski, Hyunsil Han, Kerry A. Casey, Siyu Li, Erik S. Welf, Chieh-I Chen, Dimitris Skokos, Frank Seebach, Israel Lowy, Matthew G. Fury, Melissa Mathias, Nehal J. Lakhani	5
8	A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma. 2023 ·Journal of Clinical Oncology ·Timothy J. Panella, Sajeve Thomas, Meredith McKean, Kim Margolin, Ryan Weight, (unknown), (unknown), (unknown), Mark Salvati, Israel Lowy, Matthew G. Fury, Giuseppe Gullo	1
9	Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates 2023 ·Journal of Clinical Oncology ·Julie R. Brahmer, Charles G. Drake, Ira Wollner, John D. Powderly, Joel Picus, William H. Sharfman, Elizabeth Stankevich, Alice Pons, Theresa M. Salay, Tracee L. McMiller, Marta M. Gilson, Changyu Wang, M. J. Selby, Janis M. Taube, (unknown), Lieping Chen, Alan J. Korman, Drew M. Pardoll, Israel Lowy, Suzanne L. Topalian	31
10	Tolerability and antitumor activity of cemiplimab, a human monoclonal anti–PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort 2021 ·Lung Cancer ·Víctor Moreno, Pilar Garrido, Kyriakos P. Papadopoulos, Maria J. de Miguel, Marta Gil-Martín, Raid Aljumaily, Lee S. Rosen, Petra Rietschel, Kosalai Kal Mohan, Suk‐Young Yoo, Elizabeth Stankevich, Israel Lowy, Matthew G. Fury	11
11	1269P EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC) 2020 ·Annals of Oncology ·Byoung Yong Shim, (unknown), Javier de Castro, (unknown), Manuel Cobo, Hye Ryun Kim, Jeong‐Seon Ryu, M. Majem Tarruella, Yvonne Summers, Christian A. Thomas, Yadan Xu, Israel Lowy, Petra Rietschel	7
12	Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma 2019 ·Blood ·Dennis Cooper, Deepu Madduri, Suzanne Lentzsch, Sundar Jagannath, Jingjin Li, Anita Boyapati, Lieve Adriaens, (unknown), Min Zhu, Israel Lowy, David M. Weinreich, George D. Yancopoulos, Manish Sharma, Maria Karasarides, David Sternberg	31
13	Tumor-reprogrammed resident T cells resist radiation to control tumors 2019 ·Nature Communications ·Ainhoa Arina, Michael A. Beckett, Christian Fernandez, Wenxin Zheng, Sean P. Pitroda, Steven J. Chmura, Jason J. Luke, (unknown), Yuzhu Hou, Byron Burnette, Helena J. Mauceri, Israel Lowy, Tasha N. Sims, Nikolai N. Khodarev, Yang-Xin Fu, Ralph R. Weichselbaum	161
14	First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies 2019 ·Clinical Cancer Research ·Kyriakos P. Papadopoulos, Melissa L. Johnson, A. Craig Lockhart, Kathleen N. Moore, Gerald S. Falchook, Silvia C. Formenti, Aung Naing, Richard D. Carvajal, Lee S. Rosen, Glen J. Weiss, Rom S. Leidner, Jingjin Li, Anne Paccaly, Minjie Feng, Elizabeth Stankevich, Israel Lowy, Matthew G. Fury, Marka R. Crittenden	50
15	Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade 2016 ·Cancer Research ·Alexandra Eichten, (unknown), Alexander P. Adler, Li Zhang, Ella Ioffe, Asma Parveen, George D. Yancopoulos, John S. Rudge, Israel Lowy, Hsin Chieh Lin, Douglas MacDonald, Christopher Daly, Xunbao Duan, Gavin Thurston	47
16	A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors 2015 ·Clinical Cancer Research ·Kyriakos P. Papadopoulos, Robin Kate Kelley, Anthony W. Tolcher, Albiruni R. Abdul Razak, Katherine Van Loon, Amita Patnaik, Philippe L. Bédard, (unknown), Muralidhar Beeram, Lieve Adriaens, Carrie Brownstein, Israel Lowy, Ana Kostić, Pamela A. Trail, Bo Gao, A. Thomas DiCioccio, Lillian L. Siu	59
17	Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma 2009 ·Clinical Cancer Research ·Stephen M. Ansell, Sara A. Hurvitz, Patricia Koenig, Betsy LaPlant, Brian Kabat, (unknown), Thomas M. Habermann, David J. Inwards, Meena Verma, Reiko Yamada, Charles Erlichman, Israel Lowy, John M. Timmerman	263
18	Immune Activation Driven by CTLA-4 Blockade Augments Viral Replication at Mucosal Sites in Simian Immunodeficiency Virus Infection 2008 ·The Journal of Immunology ·Valentina Cecchinato, Elżbieta Tryniszewska, (unknown), Monica Vaccari, Adriano Boasso, Wen-Po Tsai, Constantinos Petrovas, Dietmar Fuchs, Jean‐Michel Héraud, David Venzon, Gene M. Shearer, Richard A. Koup, Israel Lowy, Christopher J. Miller, Genoveffa Franchini	110
19	Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4 breakdown → 2006 ·Journal of Clinical Oncology ·(unknown), Joseph Blansfield, Khoi Q. Tran, Andrew L. Feldman, Marybeth S. Hughes, Richard E. Royal, Udai S. Kammula, Suzanne L. Topalian, Richard M. Sherry, David E. Kleiner, Martha Quezado, Israel Lowy, Michael Yellin, Steven A. Rosenberg, James Chih‐Hsin Yang	646
20	Phase I study of a neutralizing monoclonal anti-CTLA4 antibody (MDX-010) in patients with relapse of malignancy after allogeneic hematopoietic stem cell transplantation 2005 ·Biology of Blood and Marrow Transplantation ·Asad Bashey, Bridget Medina, (unknown), Jiehua Zhou, Ewa Carrier, Januario E. Castro, Peter Holman, T.A. Lane, Catherine Q. Sun, Israel Lowy, Sue Corringham, Robert J. Soiffer, James R. Mason, Edward D. Ball	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact